BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 31, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/28 cls
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Ladenburg Thalmann Juan Sanchez Upgrade Buy (from neutral) 8% $14.64
Sanchez reiterated an $18 target. He noted AMAG could end 1Q12 with $230M in cash and the current valuation of $287M would assign a technology value of $50-$60M, which he believes is low. Earlier this month, AMAG terminated a proposed merger with cancer company Allos Therapeutics Inc. (NASDAQ:ALTH) after AMAG shareholders voted against the deal (see BioCentury, Oct. 24). AMAG markets Feraheme ferumoxytol in the U.S. to treat...

Read the full 617 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >